Cellectar Biosciences Provides Phospholipid Drug Conjugate (PDC) Platform Development Update
02 November 2015 - 2:30PM
Cellectar Biosciences, Inc. (NASDAQ:CLRB), an oncology-focused
biotechnology company, today provides an update on its recently
initiated Phospholipid Drug Conjugate (PDC) chemotherapeutic
program, CLR CTX.
PDCs are a new class of small-molecules that employ Cellectar's
extensively validated phospholipid ether-based cancer targeting and
delivery vehicle. The PDC platform possesses the ability to link
diverse oncologic payloads for targeted delivery to a broad range
of cancers.
The objective of the CLR CTX program is to develop PDC
chemotherapeutics through conjugation of our delivery vehicle and
multiple non-targeted anti-cancer agents to improve therapeutic
indices and expand potential indications through the targeted
delivery of chemotherapeutic payloads.
"The potential advantages of drug candidates developed using the
PDC delivery platform over classic cytotoxic approaches are
broad-band tumor targeting, including brain metastases, and
prolonged tumor cell retention, both of which have been validated
by human imaging. Further, PDC delivery technology has demonstrated
the ability to target human glioma stem cells ex vivo, suggesting
the potential to provide targeted delivery of therapeutic agents to
cancer stem cells," said John S. Kuo, MD, PhD, FAANS, FACS,
Associate Professor of Neurological Surgery and Human Oncology
(Tenure) Director, Comprehensive Brain Tumor Program Chair, CNS
Tumors Working Group, Carbone Cancer Center, Center for Stem Cell
and Regenerative Medicine at the University of
Wisconsin-Madison.
CLR CTX Preclinical Update
The company introduced its Phospholipid Drug Conjugate (PDC)
platform for the targeted delivery of chemotherapeutics during its
second quarter financial results call in August, 2015. Since then
the company has completed the first phase of its PDC
chemotherapeutic preclinical proof of concept research, including
in vitro evaluation of multiple conjugated paclitaxel analogs. A
key outcome of this evaluation was the identification of a lead
paclitaxel analog, CLR 1603-PTX, for advancement to in vivo
studies. Further details about the results of CLR 1603-PTX in vitro
evaluation will be presented during the company's third quarter
financial results call later this month.
"The sense of urgency demonstrated by our R&D team and the
resulting progress with our CLR CTX program since we announced it
two months ago is reflective of the potential of our PDC platform
to create new targeted treatments for cancer," said Jim Caruso,
president and CEO of Cellectar Biosciences. "To date, we have
successfully developed multiple conjugated paclitaxel analogs,
completed necessary in vitro work and are now advancing to in vivo
studies."
CLR 1603-PTX in vivo safety and efficacy evaluation will now be
conducted in animal tumor models in order to demonstrate the
chemotherapeutic payload targeting efficacy of the PDC delivery
platform.
About Phospholipid Drug Conjugates (PDCs)
Cellectar's PDC platform has demonstrated highly selective
cancer targeting both preclinically in over 60 in vivo cancer
models, and subsequently confirmed clinically in over 10 cancer
types. The platform's payload diversity has been validated using
cytotoxic radioisotopes for cancer therapy; PET imaging isotopes
for cancer imaging; fluorophores for image-guided surgery, and now
the company plans to expand its payload portfolio to
chemotherapeutics with further preclinical study of paclitaxel and
other non-targeted anti-cancer agents with both in-house and
collaborative R&D efforts.
Cellectar's lead PDC is CLR 131. Its payload is iodine-131, a
proven cytotoxic radioisotope that is used primarily for thyroid
cancer treatment. The company initiated a disease-specific Phase 1
dose escalation study in patients with relapsed or refractory
multiple myeloma this past April, and has been granted orphan drug
designation. The company expects to evaluate cohort 1 and initiate
cohort 2 during the first half of 2016. The primary objective of
the study is to assess the safety and tolerability of CLR 131 in
this patient population with secondary objectives of establishing
the recommended Phase 2 dose and characterizing therapeutic
activity.
About Cellectar Biosciences, Inc. Cellectar
Biosciences is developing phospholipid drug conjugates (PDCs)
designed to provide cancer targeted delivery of diverse oncologic
payloads to a broad range of cancers and cancer stem cells.
Cellectar's PDC platform is based on the company's proprietary
phospholipid ether analogs. These novel small-molecules have
demonstrated highly selective uptake and retention in a broad range
of cancers. Cellectar's PDC pipeline includes product candidates
for cancer therapy and cancer diagnostic imaging. The company's
lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic
radioisotope, as its payload. CLR 131 is currently being evaluated
under an orphan drug designated Phase 1 study in patients with
relapsed or refractory multiple myeloma. The company is also
developing PDCs for targeted delivery of chemotherapeutics such as
paclitaxel (CLR 1603-PTX), a preclinical stage product candidate,
and plans to expand its PDC chemotherapeutic pipeline through both
in-house and collaborative R&D efforts. For additional
information please visit www.cellectarbiosciences.com.
This news release contains forward-looking statements. You can
identify these statements by our use of words such as "may,"
"expect," "believe," "anticipate," "intend," "could," "estimate,"
"continue," "plans," or their negatives or cognates. These
statements are only estimates and predictions and are subject to
known and unknown risks and uncertainties that may cause actual
future experience and results to differ materially from the
statements made. These statements are based on our current beliefs
and expectations as to such future outcomes. Drug discovery and
development involve a high degree of risk. Factors that might cause
such a material difference include, among others, uncertainties
related to the ability to raise additional capital, uncertainties
related to the ability to attract and retain partners for our
technologies, the identification of lead compounds, the successful
preclinical development thereof, the completion of clinical trials,
the FDA review process and other government regulation, our
pharmaceutical collaborators' ability to successfully develop and
commercialize drug candidates, competition from other
pharmaceutical companies, product pricing and third-party
reimbursement. A complete description of risks and uncertainties
related to our business is contained in our periodic reports filed
with the Securities and Exchange Commission including our Form
10-K/A for the year ended December 31, 2014. These
forward-looking statements are made only as of the date hereof, and
we disclaim any obligation to update any such forward-looking
statements.
CONTACT: INVESTOR AND MEDIA CONTACT:
Jules Abraham
JQA Partners
917-885-7378
jabraham@jqapartners.com
Cellectar Biosciences (NASDAQ:CLRBW)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Cellectar Biosciences (NASDAQ:CLRBW)
Historical Stock Chart
Von Jul 2023 bis Jul 2024